Connect with us

Market

Coming to the OTCQB, 2015 the Year of Oxis International (OTCMKTS:OXIS) Continues

Published

on

Oxis International (OTCQB:OXIS) has had quite the year. Right after the new year OXIS announced patent licensing for Multiple Myeloma treatments, as well as releasing press of Dr. James J Mulé to the scientific advisory board. The cherry on the sundae, so to speak, may have come last week with the announcement of OXIS being up-listed to the OTCQB.

Unless you’re new to the small cap or micro cap game, this probably isn’t the first time you’ve heard about a company getting “up-listed” and it certainly won’t be the last. Many people don’t really understand the importance of up-listing and how it can be a real game changer for the company.

There are many advantages for a company that gets up-listed but as with all good things, there are some disadvantages too. Let’s take a take a look at both sides of the coin.

Some of the advantages to a stock getting up-listed include:

  1. Exposure to more favorable financing options
  2. Increased investor confidence due to reporting requirements of the exchange
    1. IE companies need to identify an accurate share structure, list the law firm responsible for handling the company’s annual report(s), etc.
  3. Minimum prices per share will be maintained due to the requirements of the exchange
    1. For OTCQB, companies need to meet an ongoing minimum bid price test of $0.01 as of the close of business for at least one of every 30 calendar days
  4. A heightened sense of corporate responsibility by way of additional reporting by companies regarding information on officers, directors, and controlling shareholders.

If you are an investor with your eye on a company, like OXIS, that is moving up to another exchange, those are just a few of the positive things, among others.

Of course, there are also negative things to be warry of. If the company is struggling financially, coming up with the $10,000 (minimum) annual fee and one time application fee of $2,500 to upgrade to the OTCQB, could mean even more hardship for the company. Not to mention, if the company currently is already trading on the line of the minimum, it could end up having a hard time meeting the minimum price lives that are required of a company on the OTCQB.

But for those doing their DD, if the company is making the jump “the QB”, you would hope as an investor, that the company wouldn’t make that big jump if they didn’t have all their ducks in a row.  For investors, the upside is, if a company they are watching is making that jump, chances are a certain level of transparency

Should exist with the company and in turn can become a strong focus for investors.

Playing with the Big Boys

Moving up can be a definite game changer for the future of a company. Establishing transparency is key in maintaining confidence of investors. Being able to have a clear picture of the financial situation of a company is one of the most important things to making smart investing decisions. And for some companies, if things go well on the OTCQB, they set their sights on the NASQAQ or NYSE.

Hopefully a Happy Ending

In conclusion, there are a host of ways a company can attract investors. From hitting today’s social media market, to hiring of a professional investor relations firm, the ultimate outcome depends on the financial health and transparency of the company in question.

Biotech

CytoDyn Inc (OTCMKTS:CYDY) Regains Momentum After The Big Announcement

Published

on

By

Now that the market seems to be coming back into his elements, it could be time for investors to start looking into penny stocks more closely. These stocks may often be risky, but if one makes the right choice, then the rewards could be enormous. One penny stock that could be put into the watch list at this point in time is that of CytoDyn Inc (OTCMKTS:CYDY).

The late-stage biotechnology company, which is developing the coronavirus medicine leronlimab, announced last week that it had filed a comprehensive application for uplisting on NASDAQ. The company announced that it believes that its application satisfies the myriad listing requirements of the NASDAQ Capital Market.

The Chief Executive Officer and President of the company Nader Pourhassan stated that while it is true that the entire process is expected to take many weeks, CytoDyn is hopeful of success in this matter.

He went on to state that a listing on NASDAQ will not only provide shareholders with more liquidity but also give CytoDyn much bigger access to fresh capital. It is a significant development for the company, and the market participants realized it as well. After the announcement was made, the stock rallied by as much as 50%. Investors could do well to keep an eye on the stock this week.

While the rally following this announcement was a welcome relief for the company, it is important to point out that earlier on in the week, the stock has fallen considerably following a setback. Last Monday, the company announced that the United States Food and Drug Administration handed CytoDyn a refusal to file a letter with regards to the usage of leronlimab to treat HIV.

However, at the same time, investors should be noted that the company did announce that it is confident of furnishing the agency with all the further details that have been demanded. It is one of the penny stocks that have performed remarkably well this year so far, and investors could keep an eye on it.

Continue Reading

Market

These 3 Pot Stocks Are Up Big Since May: What’s the Buzz?

Published

on

By

Over the course of the past year or so, pot stocks had generally struggled, but during the past month, those stocks have recovered nicely. The stock market suffered a historic fall due to the economic turmoil caused by the coronavirus pandemic. It is believed that investors who are looking for value have descended on the beaten-down pot stocks. On the flip side, these stocks could also have been identified as defensive plays in an uncertain market environment.

That being said, it should be noted that despite the gains recorded by many stocks, most of those stocks are still considerably lower than the all-time highs. In such a situation, it could be worthwhile for investors to take a closer look at some of the strongest and more stable cannabis companies in the industry. Here is a look at three pot stocks that made significant moves in May and could be tracked by investors at this point.

1. HEXO Stock Jumps Ahead of Earnings

HEXO Corp (TSX:HEXO) (NYSE:HEXO) is one of those cannabis companies which have had a particularly tough time over the past year or so. However, the stock has emerged as one of the bigger gainers among pot stocks in recent trading sessions. The Hexo stock has gained as much as 120% over the course of the past month. The company is all set to release its financial results for the fiscal third quarter on Thursday, and hence, it could be a big week for the stock.

The recent surge in the Hexo stock may have come as a major boost to investors, but it should be noted that over the past year, it recorded considerable losses. The beaten-down nature of the stock may have contributed to the stock becoming more attractive for investors. However, the trajectory of the Hexo stock in the near term is going to depend a lot on its third-quarter earnings.

The company had made a loss of $298 million in the previous quarter, and while it is almost certain that it is going to make a loss again, the size of the loss is going to be keenly watched. Additionally, any writedowns are also going to be harmful to the stock. Investors should also keep an eye on sales growth.

2 Organigram gains Momentum on Value Buying

Organigram Holdings (TSX:OGI) (NASDAQ:OGI) is another pot stock that has made significant gains in the past month. Since May 13, the stock has gained as much as 80%. In April, the company announced its fiscal second-quarter results, but it had been a disappointment.

Revenues dropped by 13.7% year on year to hit CA$23.2 million, and losses widened to CA$6.8 million from CA$6.4 million in the prior-year period. However, one significant cause for optimism for Organigram investors is the fact that in the second quarter, cannabis 2.0 products made up as much as 13% of its revenue. That has opened up a whole new opportunity for the company.

Wholesale cannabis revenue made up 24% of the net, and that is again a new source of revenue. The company blamed the lower volumes of flower as well as cannabis oil for the drop in sales. Organigram reported cash and cash equivalents of CA$41.1 million as of February 29. Considering the fact that it has burned CA$25 million in the past six months, investors should not use that the cash balance does not paint a pretty picture.

3 Aphria Recovers Following Solid Earnings

Aphria (TSX:APHA) (NYSE:APHA), on the other hand, managed to perform relatively well in its fiscal third quarter. The net sales rose by as much as 19.7% sequentially to hit CA$144.4 million, and more importantly, the company also managed to record a profit for the third time in four quarters. On top of that, it should be noted that although the Canadian cannabis company spends CA$124.4 million on its operations in the nine months trailing that quarter, it still reported a cash balance of CA$515 million.

The performance seems to have buoyed market participants as well, and the stock has rallied by as much as 75% since the middle of May. One of the most important things that investors are going to be looking into is whether Aphria is going to be able to maintain its profitability.

However, due to the turmoil caused by the coronavirus pandemic, it might prove difficult. That being said, it should be noted that the pandemic is going to have an equally damaging effect across the sector.

Continue Reading

Market

ConforMIS Inc (NASDAQ: CFMS): Premium Members Made A Quick 65% Profit In Just 1 week

Published

on

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/
JOIN US NOW: For Details Contact us at info@tradersinsights.com

Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy ConforMIS Inc (NASDAQ: CFMS) yesterday (march 13th) at $1.36. Now look at the price of the stock – its up 65% at $2.25 from our buy price. This is how easy money they made. If you had invested $5,000 in CFMS, it could had been moved up to $8,250. It’s not yet late, join us at info@tradersinsights.com

Continue Reading
Advertisement

Trending